Stanley Perlman Selected Research

Cytokines

12/2022	SARS-CoV-2 infection of sustentacular cells disrupts olfactory signaling pathways.
1/2022	Effective Interferon Lambda Treatment Regimen To Control Lethal MERS-CoV Infection in Mice.
1/2021	Severe Acute Respiratory Syndrome Coronavirus 2-Induced Immune Activation and Death of Monocyte-Derived Human Macrophages and Dendritic Cells.
1/2021	Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19.
1/2021	Middle East respiratory syndrome coronavirus Spike protein variants exhibit geographic differences in virulence.
1/2020	Evaluation of Activation and Inflammatory Activity of Myeloid Cells During Pathogenic Human Coronavirus Infection.
1/2020	Murine Coronavirus Infection Activates the Aryl Hydrocarbon Receptor in an Indoleamine 2,3-Dioxygenase-Independent Manner, Contributing to Cytokine Modulation and Proviral TCDD-Inducible-PARP Expression.
1/2019	IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes.
1/2017	Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.
4/2015	Severe acute respiratory syndrome coronaviruses with mutations in the E protein are attenuated and promising vaccine candidates.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stanley Perlman Research Topics

Disease

75	Infections 03/2024 - 09/2005
43	COVID-19 03/2024 - 01/2020
20	Coronavirus Infections 12/2023 - 09/2005
16	Virus Diseases (Viral Diseases) 01/2022 - 06/2005
12	Severe Acute Respiratory Syndrome 01/2022 - 09/2005
10	Demyelinating Diseases (Demyelinating Disease) 11/2020 - 07/2002
9	Inflammation (Inflammations) 12/2022 - 10/2011
7	Pneumonia (Pneumonitis) 01/2022 - 01/2014
4	Weight Loss (Weight Reduction) 10/2023 - 02/2015
4	Encephalitis (Encephalitis, Rasmussen) 08/2014 - 10/2003
3	Encephalomyelitis (Myeloencephalitis) 10/2021 - 07/2011
3	Human Influenza (Influenza) 01/2021 - 11/2006
2	Edema (Dropsy) 01/2023 - 01/2022
2	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022 - 10/2015
2	Lung Injury 01/2021 - 04/2015
2	Acute Lung Injury 01/2019 - 01/2017
2	West Nile Fever 12/2016 - 08/2016
2	Emerging Communicable Diseases (Emerging Infectious Diseases) 03/2016 - 02/2016
2	Multiple Sclerosis 03/2005 - 02/2004
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 08/2023
1	Interstitial Lung Diseases (Interstitial Lung Disease) 06/2022
1	Breakthrough Infections 06/2022
1	Rheumatic Diseases (Rheumatism) 06/2022
1	COVID-19 breakthrough infections 06/2022
1	Reinfection 01/2022
1	Hemorrhage 01/2022
1	Pathologic Processes 01/2022
1	Vesicular Stomatitis 01/2022

Drug/Important Bio-Agent (IBA)

33	VaccinesIBA 03/2024 - 04/2014
32	Proteins (Proteins, Gene)FDA Link 10/2023 - 09/2005
21	CytokinesIBA 12/2022 - 02/2004
16	Antiviral Agents (Antivirals)IBA 12/2023 - 01/2007
14	Neutralizing AntibodiesIBA 08/2023 - 10/2002
9	EpitopesIBA 01/2022 - 02/2004
8	AntibodiesIBA 03/2024 - 03/2005
8	InterferonsIBA 03/2024 - 10/2010
8	ChemokinesIBA 01/2020 - 02/2004
7	Messenger RNA (mRNA)IBA 03/2024 - 04/2015
6	COVID-19 VaccinesIBA 10/2023 - 01/2020
6	AntigensIBA 01/2023 - 04/2003
5	Angiotensin-Converting Enzyme 2IBA 01/2024 - 01/2007
5	Prostaglandin D2IBA 01/2022 - 01/2017
5	Interleukin-10 (Interleukin 10)IBA 01/2020 - 03/2011
4	Interferon-gamma (Interferon, gamma)IBA 01/2021 - 07/2002
4	Peptide Hydrolases (Proteases)FDA Link 01/2021 - 05/2014
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 10/2010
4	RNA (Ribonucleic Acid)IBA 01/2018 - 09/2015
3	Broadly Neutralizing AntibodiesIBA 10/2023 - 01/2017
3	EndoribonucleasesIBA 01/2022 - 01/2017
3	Glycoproteins (Glycoprotein)IBA 01/2022 - 03/2008
3	Phospholipases (Phospholipase)IBA 01/2022 - 10/2015
3	Transcription Factors (Transcription Factor)IBA 01/2020 - 01/2007
2	mRNA VaccinesIBA 01/2023 - 10/2022
2	EicosanoidsIBA 01/2022 - 04/2021
2	Therapeutic UsesIBA 01/2022 - 07/2011
2	prostaglandin D2 receptorIBA 01/2022 - 04/2021
2	asapiprantIBA 01/2022 - 04/2021
2	Uridylate-Specific EndoribonucleasesIBA 01/2022 - 12/2021
2	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2022 - 12/2021
2	InterleukinsIBA 01/2021 - 01/2020
2	EnzymesIBA 12/2020 - 10/2020
2	NAD (NADH)IBA 12/2020 - 10/2020
2	Niacinamide (Nicotinamide)FDA LinkGeneric 12/2020 - 10/2020
2	nicotinamide-beta-ribosideIBA 12/2020 - 10/2020
2	Immunoglobulin G (IgG)IBA 01/2019 - 03/2016
2	Viral ProteinsIBA 01/2017 - 02/2007
2	Subunit VaccinesIBA 01/2017 - 03/2016
2	Immunoglobulins (Immunoglobulin)IBA 01/2017 - 12/2016
2	Interferon Type IIBA 02/2016 - 02/2016
2	Chemotactic FactorsIBA 03/2013 - 06/2005
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 03/2013 - 06/2005
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 03/2009 - 07/2006
1	Viral RNAIBA 01/2023
1	N-(2-cyanoethylene)urea (BA 1)IBA 01/2023
1	nirmatrelvirIBA 01/2023
1	Cysteine Proteases (Cysteine Protease)IBA 01/2023
1	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 01/2023
1	PolyproteinsIBA 01/2023
1	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2023
1	Caspase 6IBA 01/2023
1	DNA-Directed RNA Polymerases (RNA Polymerase)IBA 01/2023
1	Rituximab (Mabthera)FDA Link 06/2022
1	SARS-CoV-2 spike proteinIBA 01/2022
1	Lipid NanoparticlesIBA 01/2022
1	IgYIBA 01/2022
1	2-5A-dependent ribonuclease (RNase L)IBA 01/2022
1	Interferon LambdaIBA 01/2022
1	Liposomes (Liposome)IBA 01/2022
1	Phospholipases A2 (Phospholipase A2)IBA 01/2022
1	oridoninIBA 12/2021
1	Codon (Codons)IBA 01/2021
1	Chemokine CXCL10IBA 01/2021
1	Protease Inhibitors (Protease Inhibitor)IBA 01/2021
1	Protein Kinases (Protein Kinase)IBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	pifithrinIBA 01/2021
1	CyclohexaneIBA 01/2021

Therapy/Procedure

18	Therapeutics 01/2024 - 01/2007
1	Intranasal Administration 01/2022
1	Personal Protective Equipment 01/2021